Gauting, Germany-based pharma firm Ventaleon has appointed Dr Ulrich Dauer – a biotech executive and entrepreneur – as its chief executive officer at a time when the company enters late-stage clinical development.
Dauer has several years of senior executive management experience serving Activaero – a private German pharma firm now owned by Vectura – as its chief strategy officer and subsequently at Berlin-based OMEICOS Therapeutics where he was chief executive officer.
He said: “I know Ventaleon’s technology very well from my time at Activaero and believe that the novel inhaled antiviral agents that Ventaleon is developing has the potential to help patients suffering from serious infections such as influenza to get better, faster.
“I very much look forward to growing the company and advancing it into the next stages of development.”
Prior to his time at Activaero, Dauer founded 4SC AG, a biopharmaceutical company that focuses on cancer treatments, and served as its CEO for fourteen years.
Jean Luechinger, chairman of Ventaleon’s supervisory board, said: “We are very pleased to have Dauer lead Ventaleon.
“He is joining the company at a critical time as it advances into late-stage clinical development.
“With many years of effectively leading biotechs, forming strong collaborations with the pharmaceutical industry and successfully completing major financial transactions, Dauer has the ideal skill set to take Ventaleon to the next stage of growth.”
Dauer succeeds Gerhard Scheuch who will continue to serve as a member of the supervisory board of Ventaleon.